Deconstructing the Molecular Portraits of Breast Cancer

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2010 Dec 15

PMID 21147047

Citations 638

Authors

Aleix Prat

Charles M Perou

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a heterogeneous disease in terms of histology, therapeutic response, dissemination patterns to distant sites, and patient outcomes. Global gene expression analyses using high-throughput technologies have helped to explain much of this heterogeneity and provided important new classifications of cancer patients. In the last decade, genomic studies have established five breast cancer intrinsic subtypes (Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like) and a Normal Breast-like group. In this review, we dissect the most recent data on this genomic classification of breast cancer with a special focus on the Claudin-low subtype, which appears enriched for mesenchymal and stem cell features. In addition, we discuss how the combination of standard clinical-pathological markers with the information provided by these genomic entities might help further understand the biological complexity of this disease, increase the efficacy of current and novel therapies, and ultimately improve outcomes for breast cancer patients.

Citing Articles

miR-1297 is frequently downmodulated in flat epithelial atypia of the breast and promotes mammary neoplastic transformation via EphrinA2 regulation.

Scafetta G, Rampioni Vinciguerra G, Giglio S, Faruq O, Cirombella R, Segatto I J Exp Clin Cancer Res. 2025; 44(1):96.

PMID: 40082972 PMC: 11908103. DOI: 10.1186/s13046-025-03354-2.

Establishing a cryopreserved biobank of living tumor tissues for drug sensitivity testing.

Chen P, Zhou J, Chu X, Feng Y, Zeng Q, Lei J Bioact Mater. 2025; 46:582-596.

PMID: 40061435 PMC: 11889390. DOI: 10.1016/j.bioactmat.2024.09.008.

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets.

Felsheim B, Fernandez-Martinez A, Fan C, Pfefferle A, Hayward M, Hoadley K NPJ Breast Cancer. 2025; 11(1):24.

PMID: 40057511 PMC: 11890565. DOI: 10.1038/s41523-025-00740-z.

Synergistic anticancer effects of mitochondria-targeting peptide combined with paclitaxel in breast cancer cells: a preclinical study.

Ahn J, Kim O, Jin S, Ryu J, Lee D, Park W Ann Surg Treat Res. 2025; 108(2):108-123.

PMID: 39944924 PMC: 11813545. DOI: 10.4174/astr.2025.108.2.108.

Subtype-specific role for Jagged1 in promoting or inhibiting breast tumor formation.

Chung W, Wang W, Challagundla L, Moore C, Egan S, Xu K Oncogenesis. 2025; 14(1):2.

PMID: 39890784 PMC: 11785972. DOI: 10.1038/s41389-025-00545-6.

References

Minn A, Gupta G, Siegel P, Bos P, Shu W, Giri D . Genes that mediate breast cancer metastasis to lung. Nature. 2005; 436(7050):518-24. PMC: 1283098. DOI: 10.1038/nature03799. View

Turner N, Reis-Filho J, Russell A, Springall R, Ryder K, Steele D . BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2006; 26(14):2126-32. DOI: 10.1038/sj.onc.1210014. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Kenny P, Lee G, Myers C, Neve R, Semeiks J, Spellman P . The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2008; 1(1):84-96. PMC: 2391005. DOI: 10.1016/j.molonc.2007.02.004. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

Resetkova E, Reis-Filho J, Jain R, Mehta R, Thorat M, Nakshatri H . Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat. 2009; 123(1):97-108. DOI: 10.1007/s10549-009-0619-3. View

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

Menendez J, Mehmi I, Lupu R . Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol. 2006; 24(23):3735-46. DOI: 10.1200/JCO.2005.04.3489. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

10.

Vu-Nishino H, Tavassoli F, Ahrens W, Haffty B . Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys. 2005; 62(4):1040-7. DOI: 10.1016/j.ijrobp.2005.01.008. View

11.

Chaffer C, Weinberg R . Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell. 2010; 7(3):271-2. PMC: 2941878. DOI: 10.1016/j.stem.2010.08.008. View

12.

Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger-Saal S, Lovgren K . The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008; 10(3):R53. PMC: 2481503. DOI: 10.1186/bcr2108. View

13.

Weigelt B, Hu Z, He X, Livasy C, Carey L, Ewend M . Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005; 65(20):9155-8. DOI: 10.1158/0008-5472.CAN-05-2553. View

14.

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

15.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98(4):262-72. DOI: 10.1093/jnci/djj052. View

16.

Fan C, Oh D, Wessels L, Weigelt B, Nuyten D, Nobel A . Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006; 355(6):560-9. DOI: 10.1056/NEJMoa052933. View

17.

Lipton A, Ali S, Leitzel K, Demers L, Harvey H, Chaudri-Ross H . Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003; 21(10):1967-72. DOI: 10.1200/JCO.2003.09.098. View

18.

Suspitsin E, Sokolenko A, Voskresenskiy D, Ivantsov A, Shelehova K, Klimashevskiy V . Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. Breast Cancer. 2009; 18(2):137-40. DOI: 10.1007/s12282-009-0105-0. View

19.

Visvader J . Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009; 23(22):2563-77. PMC: 2779757. DOI: 10.1101/gad.1849509. View

20.

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View